NCT04201262 2025-10-14
An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
Clinical Trials
7 trialsNCT04155424 2024-09-25
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
Alexion Pharmaceuticals, Inc.
Phase 2/3 Terminated
NCT02003144 2022-08-23
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
Alexion Pharmaceuticals, Inc.
Phase 3 Completed
NCT01892345 2019-06-26
A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
Alexion Pharmaceuticals, Inc.
Phase 3 Terminated
NCT02276963 2019-06-06
Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses
Johns Hopkins University
Phase 1 Completed
NCT02166346 2018-04-17
Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)
Johns Hopkins University
Phase 2 Completed
NCT00179478 2017-09-06
CHAMPIONS10
Beth Israel Deaconess Medical Center
Phase 4 Completed